The online version of this article (doi:10.1186/1897-4287-12-8) contains supplementary material, which is available to authorized users.
The authors declare that they have no competing interest.
WASJ conceived the study. NMC participated in the study design, conducted the mutation analysis, statistical analysis and manuscript preparation. VEFF participated in the study design, acquisition of data, statistical analysis and revised the manuscript critically. All authors read and approved the final manuscript.
Approximately 5-10% of breast cancers are hereditary. Among hereditary syndromes, Hereditary Breast and Ovarian Cancer Syndrome (HBOC) and Li-Fraumeni Syndrome (LFS) have received the most attention. HBOC is due to mutations in the BRCA1 and BRCA2 genes and is characterized by breast adenocarcinoma and/or epithelial ovarian carcinoma. LFS is associated with germline mutations in TP53; the most frequent cancer types associated with this syndrome are sarcoma, breast cancer, leukemia, brain tumors and adrenocortical carcinomas. Other cancers related to LFS are found at lower frequencies. In Brazil, especially in the southern part of the country, a specific mutation in the TP53 gene, TP53 p.R337H, occurs at a high frequency in childhood adrenocortical tumors. It has been proposed that this mutation increases breast cancer risk in southern Brazilian women.
We carried out a case-control study to determine the prevalence of the TP53 p.R337H mutation in 28 female cancer patients attended at the Cancer Genetic Counseling Service of the General Hospital of the University of São Paulo Medical School of Ribeirão Preto who fulfilled Hereditary Breast and Ovary Cancer Syndrome genetic test criteria compared to healthy woman (controls). TP53 p.R337H mutation status was determined using the High Resolution Melting (HRM) method, followed by DNA sequencing. Fisher’s test was used to compare the prevalence of TP53 p.R337H in the patient and control groups.
Two of the breast cancer cases (7.1%) and none of the controls carried the TP53 p.R337H mutation. At the time of the investigation, both cases fulfilled testing criteria for Hereditary Breast and Ovary Cancer Syndrome but not Li-Fraumeni or Li-Fraumeni-like Syndrome, based on genetic testing criteria of NCCN Clinical Practice Guidelines in Oncology (v.1.2010).
We suggest that genetic screening of Brazilian breast cancer patients who fulfill Hereditary Breast and Ovary Cancer Syndrome criteria and have a family history that includes other tumors of the LFS/LFL spectrum be tested for the TP53 p.R337H mutation.
WHO. World Health Organization [ http://www.who.int]
INCA. National Cancer Institute Ministry of Health. Department of Health Care Coordination for Prevention and Surveillance. Estimate 2012. Rio de Janeiro: Cancer Incidence in Brazil;
Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC: Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006, 295(12):1379–1388. 10.1001/jama.295.12.1379 CrossRefPubMed
Schneider K: Counseling about cancer: strategies for genetic counseling. 2nd edition. New York: Wiley-Liss; 2002.
Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP: Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev 2001, 10(2):83–87. PubMed
Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans DGR, Thompson E, Mann JR, Martin J, Mitchell ELD, Santibanez-Koref MF: Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 1994, 54(5):1298–1304. PubMed
Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995, 25: 101–124. PubMed
Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J: P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000, 82(12):1932–1937. CrossRefPubMedPubMedCentral
NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology TM. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Li-Fraumeni Syndrome (LIFR-1). V.4; 2013. http://www.nccn.org
Lee DS, Yoon SY, Looi LM, Kang P, Kang IN, Sivanandan K, Ariffin H, Thong MK, Chin KF, Mohd Taib NA, Yip CH, Teo SH: Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients. Breast Cancer Res 2012, 14(2):R66. 10.1186/bcr3172 CrossRefPubMedPubMedCentral
Custodio G, Parise GA, Kiesel Filho N, Komechen H, Sabbaga CC, Rosati R, Grisa L, Parise IZ, Pianovski MA, Fiori CM, Ledesma JA, Barbosa JR, Figueiredo FR, Sade ER, Ibañez H, Arram SB, Stinghen ST, Mengarelli LR, Figueiredo MM, Carvalho DC, Avilla SG, Woiski TD, Poncio LC, Lima GF, Pontarolo R, Lalli E, Zhou Y, Zambetti GP, Ribeiro RC, Figueiredo BC: Impact of Neonatal Screening and Surveillance for the TP53 TP53 P.R337H Mutation on Early Detection of Childhood Adrenocortical Tumors. J Clin Oncol 2013, 31(20):2619–2626. 10.1200/JCO.2012.46.3711 CrossRefPubMedPubMedCentral
Achatz MI, Olivier M, le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, da Rocha JC, Vettore AL, Hainaut P: The TP53 mutation, TP53 P.R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007, 245(1–2):96–102. CrossRefPubMed
Assumpção JG, Seidinger AL, Mastellaro MJ, Ribeiro RC, Zambetti GP, Ganti R, Srivastava K, Shurtleff S, Pei D, Zeferino LC, Dufloth RM, Brandalise SR, Yunes JA: Association of the germline TP53 TP53 P.R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008, 8: 357. 10.1186/1471-2407-8-357 CrossRefPubMedPubMedCentral
Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI: Detailed haplotype analysis at the TP53 locus in p.TP53 P.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum Mutat 2010, 31(2):143–150. 10.1002/humu.21151 CrossRefPubMed
Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G, Marcel V, Aguiar E, Giacomazzi J, Ewald IP, Giugliani R, Hainaut P, Ashton-Prolla P: Detection of TP53 P.R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett 2008, 261(1):21–25. 10.1016/j.canlet.2007.10.044 CrossRefPubMed
NCCN - National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology™. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Hereditary Breast and/or Ovarian Cancer (HBOC-1) V.1; 2010. http://www.nccn.org
Bastien R, Lewis TB, Hawkes JE, Quackenbush JF, Robbins TC, Palazzo J, Perou CM, Bernard PS: High-throughput amplicon scanning of the TP53 gene in breast cancer using high-resolution fluorescent melting curve analyses and automatic mutation calling. Hum Mutat 2008, 29(5):757–764. 10.1002/humu.20726 CrossRefPubMed
Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res 1988, 48(18):5358–5362. PubMed
Tinat J, Bougeard G, Baert-Desurmont S, Vasseur S, Martin C, Bouvignies E, Caron O, Bressac-de Paillerets B, Berthet P, Dugast C, Bonaïti-Pellié C, Stoppa-Lyonnet D, Frébourg T: 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol 2009, 27(26):e108-e109. author reply e110 10.1200/JCO.2009.22.7967 CrossRefPubMed
Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB: An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 2001, 86(10):4970–4973. 10.1210/jcem.86.10.7957 CrossRefPubMed
Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez-Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC: Penetrance of adrenocortical tumours associated with the germline TP53 TP53 P.R337H mutation. J Med Genet 2006, 43(1):91–96. CrossRefPubMed
- TP53 p.R337H prevalence in a series of Brazilian hereditary breast cancer families
Nathalia M Cury
Victor EF Ferraz
Wilson A Silva Jr
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II